¶¶

Reporting Data Item

Business Justification

Definition

Note: Where ‘NHS Wales Data Dictionary’ the definition is as per the Data Dictionary.

Permissible Values

11. CLINICAL STATUS ASSESSMENT

11.0

ENCDv4.5b (15.1)

SPCDv1.0

(9.1)

DAHNO

Death date

To determine survival rates and mortality rates.

Date of patient’s death.

NHS Wales Data Dictionary

11.1

DAHNO

Date of clinical status assessment

To document and analyse patient activities. Required for submission to the national clinical head & neck cancer audit.

The date the clinical status assessment was undertaken post primary treatment.

11.2

DAHNO

Primary tumour status

To determine outcome in terms of disease progression / remission rates. Required for submission to the national clinical head & neck cancer audit.

The status of the primary tumour at clinical status assessment. This may need qualification according to certainty / confidence.

Permissible values are agreed by the clinical steering groups and conform to the requirements of the reporting output specifications. Currently there is no explicit requirement to map to terminologies or classifications. This will be kept under review.

•     Residual Primary Tumour

•     No Evidence of Primary Tumour

•     Recurrent Primary Tumour

•     Uncertain

11.3

DAHNO

Nodal status

To determine outcome in terms of disease progression / remission rates. Required for submission to the national clinical head & neck cancer audit.

The status of the nodal metastases at clinical status assessment. This may need qualification according to certainty / confidence.

Permissible values are agreed by the clinical steering groups and conform to the requirements of the reporting output specifications. Currently there is no explicit requirement to map to terminologies or classifications. This will be kept under review.

•     Residual Regional Nodal Metastases

•     No Evidence of Regional Nodal Metastases

•     New Regional Nodal Metastases

•     Uncertain

11.4

DAHNO

Metastatic disease status

To determine outcome in terms of disease progression / remission rates. Required for submission to the national clinical head & neck cancer audit.

The status of the distant metastases at clinical status assessment. This may need qualification according to certainty / confidence.

Permissible values are agreed by the clinical steering groups and conform to the requirements of the reporting output specifications. Currently there is no explicit requirement to map to terminologies or classifications. This will be kept under review.

•     Residual Distant Metastases

•     No Evidence of Metastases

•     New Distant Metastases

•     Uncertain